

GENTA INC DE/  
Form 8-K  
May 03, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): May 3, 2004

**GENTA INCORPORATED**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**0-19635**  
(Commission File Number)

**33-0326866**  
(IRS Employer Identification No.)

**Two Connell Drive**  
**Berkeley Heights, NJ 07922**  
(Address of Principal Executive Offices)

**07922**  
(Zip Code)

**(908) 286-9800**  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

---

**Item 5. Other Events and Regulation FD Disclosure.**

On May 3, 2004, Genta Incorporated ( Genta ) issued a press release announcing that Genta and Aventis presented results of their Phase 3 trial of Genasense (oblimersen sodium) Injection in combination with dacarbazine (DTIC) versus DTIC alone at the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA). The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated May 3, 2004

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENTA INCORPORATED

Date: May 3, 2004

By: /s/ William P. Keane

Name: William P. Keane

Title: Vice President, Chief Financial Officer  
and Corporate Secretary

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>	<b>Sequentially Numbered Page</b>
99.1	Press Release dated May 3, 2004	

---